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Abstract
Cystic tumors of the pancreas are less frequent than solid lesions and are often detected incidentally, as many of these
lesions are small and asymptomatic. However, they may be associated with pancreatitis or have malignant potential.
With advancements in diagnostic imaging, cystic lesions of the pancreas are being detected with increasing frequency.
Many lesions can cause a pancreatic cyst, most being non-neoplastic while approximately 10% are cystic tumors,
ranging from benign to highly malignant tumors. With increasing experience it is becoming clear that the prevalence
of pseudocyst among cystic lesions of the pancreas is lower than usually presumed. A presumptive diagnosis of
pseudocyst based on imaging appearance alone can cause a diagnostic error, and neoplastic cysts of the pancreas
are particularly susceptible to this misdiagnosis, which can result in inappropriate treatment. Cystic tumors of the
pancreas are formed by serous or mucinous structures showing all stages of cellular differentiation. According to the
WHO classification, they can be subdivided on the basis of their histological type and biological behavior into benign
tumors, borderline tumors, and malignant tumors. Cystic pancreatic tumors can be subdivided into peripheral (serous
cystadenomas, mucinous cystic tumors, solid and papillary epithelial neoplasms, cystic islet cell tumors), which do not
communicate with the main pancreatic duct, and ductal tumors (mucinous tumor), according to their site of origin. On
the basis of imaging criteria alone, it can be very difficult to differentiate non-tumoral cystic lesions from neoplastic
ones. The management of these patients is complex, and it is important to correlate imaging findings with knowledge
of the patient’s symptoms and of the natural history and predictors of malignancy in pancreatic cysts.
Keywords: Pancreas; pancreatic neoplasms, diagnosis; cystadenoma, diagnosis; pancreas, pathology, radiography; neoplasms,
cystic, mucinous; serous, diagnosis, pathology, radiography.
Introduction
Cystic tumors of the pancreas occur with less frequency
than solid lesions, and are often detected incidentally,
as many of these lesions are small and asymptomatic.
They may, however, be associated with pancreatitis
or have malignant potential. With advancements in
diagnostic imaging, cystic lesions of the pancreas are
increasingly being detected; in some reference centers up
to 30% of pancreatic resections are performed for cystic
tumor [1]. Accurate differentiation between cystic tumors
is important because different treatments are required
depending on the tumor’s histological type and grade.
Due to frequent lack of specific clinical and laboratory
signs and the overlap of imaging findings between
different cystic tumors and between non-neoplastic
and neoplastic cystic lesions of the pancreas [2], the
management of these patients is complex. Knowledge of
the patient’s symptoms and of the natural history and
predictors of malignancy in pancreatic cysts is important.
When dealing with pancreatic cysts, the aim of imaging
is to differentiate cystic tumors from tumor-like lesions
and to characterize the cystic tumor, distinguishing
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(a) (b) (c)
Figure 1 A 55-year-old woman with no history of pancreatitis. Mucinous cystic tumor. (a) At CT a diagnosis
of ‘pseudocyst’ was made, and it was treated with cysto-entero anastomosis. Thirteen years later a solid mass
(b) with a liver metastasis (c) can be appreciated.
(a) (b) (c)
(d) (e) (f)
Figure 2 A 75-year-old woman with a serous cystic tumor. The patient complained of abdominal pain and
a mass was palpable in the upper abdomen. At CT ((a), (b)) a large mass can be appreciated which shows
a discrete enhancement after injection of CM (b). At MR ((c)–(f)) the lesion is hyperintense on T2w images
(c), with microcystic appearance and significant dilation of the main pancreatic duct (arrowhead in (c)). With
T1w images ((d), (e)) the lesion is hypointense with significant enhancement of the septa after CM injection (e).
MRCP (f).
benign tumor, which does not usually require surgical
excision, from borderline or malignant tumor, which must
be resected whenever possible. It can be very difficult to
differentiate non-tumoral cystic lesions from neoplastic
lesions on the basis of imaging criteria alone; in order to
achieve a correct diagnosis it is important to correlate the
imaging findings with the clinical history of the patient
and the presence or absence of symptoms.
Many lesions can cause a pancreatic cyst [3]. Most
of these are non-neoplastic [4,5]; approximately 10% are
cystic tumors, ranging from benign to highly malig-
nant [6]. Although all pancreatic tumors, including ductal
adenocarcinoma, may appear as a cystic lesion as a result
of degenerative changes [7], the classical cystic neoplasms
of the pancreas are lined by different epithelium whose
morphology constitutes the main diagnostic criterion and
provides prognostic value, whereas their macroscopic
appearance (shape, volume, etc.) has no importance [8].
According to various authors, the majority (up to 90%)
of cystic lesions of the pancreas seen in clinical practice
are represented by post-inflammatory pseudocysts [4];
however, in a series of 212 consecutive patients with pan-
creatic cystic lesions observed in a reference center for
pancreatic disease, pseudocysts represented only 13.6%
of the lesions; referral bias cannot explain such a big
difference [9]. With increasing experience it is becoming
clear that the prevalence of pseudocyst in cystic lesions
of the pancreas is lower than previously thought [9,10].
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(d) (e)
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(f)
Figure 3 A 59-year-old woman with a serous cystic tumor. At US (a) a small hypoechoic lesion with no
posterior acoustic enhancement is appreciable in the body of the pancreas. The lesion shows ‘honeycomb’
architecture. At CT in the unenhanced phase (b) the lesion appears hypodense with focal bulging of
the pancreatic borders. After injection of iodinated contrast agent the lesion appears hypovascular in
the arterial (c) and pancreatic (d) phase, showing enhancement of thin septa in the center of the lesion
during the distribution phase (e). At MR the lesion is markedly hyperintense on T2 HASTE images, with
microscystic appearance (f); in this sequence a branching of the main pancreatic duct in the tail can be
observed (arrowheads). On T1w fat sat (g) the lesion appears hypointense with thin central septa which
show enhancement after injection of paramagnetic contrast agent (h). MRCP (i) confirms the microcystic
appearance; the close relationship between the cystic lesion and the m.p.d. does not allow exclusion of the
presence of a communication. However, the microcystic appearance and the normal m.p.d. allow a correct
diagnosis of serous cystic tumor.
A presumptive diagnosis of pseudocyst based on imaging
appearance alone can lead to a diagnostic error in up to
50% of cases [9,11,12], and neoplastic cysts of the pancreas
are particularly susceptible to this misdiagnosis [13],
resulting in inappropriate treatment [14,15] (Fig. 1). In a
comparison of incidental pancreatic cystic lesions [9], the
incidence of pseudocyst was significantly higher in the
group of symptomatic patients with a previous history
of pancreatitis (26/29: 89.6%) than in the asymptomatic
group (3/29: 10.4%). Thus, to make a confident diagnosis
of pseudocyst it is necessary to correlate with the clinical
history of the patient; previous chronic or severe acute
pancreatitis is a useful predictor for the diagnosis of
pseudocyst. However, in the same study, 25/42 (52%)
of the patients with a history of pancreatitis had a
cystic tumor of the pancreas [9]; thus previous pancreatitis
cannot exclude the presence of a cystic tumor.
From an imaging point of view, it is important to
confirm or exclude a communication between the cystic
lesion and the main pancreatic duct (m.p.d.). Cystic
pancreatic tumors can be subdivided into peripheral
(serous cystadenomas, mucinous cystic tumors, solid and
papillary epithelial neoplasms, cystic islet cell tumors),
which do not communicate with the m.p.d., and ductal
tumors (mucinous tumor), according to their site of
origin, although in a multi-institutional retrospective
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(b)
Figure 4 A 47-year-old man with a serous cystic
tumor. At MRCP (a) the lesion shows microcystic
appearance with unclear communication with the
m.p.d. The ERCP (b) shows an impression in the
m.p.d., but no communication, thus allowing a correct
diagnosis of serous cystic tumor.
study a communication between the lesion and the
pancreatic duct was discovered in 0.6% of those
with serous cystadenoma, 6% of those with mucinous
cystadenoma, and 10% of those with mucinous cystic
adenocarcinoma [13].
Cystic tumors of the pancreas are formed by serous or
mucinous structures showing all stages of cellular differ-
entiation. According to the WHO classification [8], they
can be subdivided on the basis of their histological type
and biological behavior into benign tumors, borderline
tumors, and malignant tumors [16].
Serous cystadenoma
Serous cystadenoma (SCA) occurs primarily in female
patients in their fifties. It involves mainly the head of the
pancreas, although it can be found in every part of the
gland [17]. Histologically, it is composed of multiple cysts
formed by glycogen-rich, PAS-positive epithelial cells. It
is a benign lesion, and no more than 10 cases of serous
cystadenocarcinoma have been published [18,19].
It is important to obtain a certain diagnosis of SCA in
a non-invasive way, as if the lesion is asymptomatic, it
is possible to leave it unresected and to follow it up [17].
A large lesion can be responsible for obstructive chronic
pancreatitis, thus indicating a need for surgical resection
(Fig. 2) [20].
SCA is generally asymptomatic and is discovered
incidentally during imaging studies performed for signs
and symptoms not related to the pancreas. Symptomatic
patients may complain of discomfort, while more serious
symptoms due to larger lesions, such as jaundice,
palpable mass and upper GI tract obstruction, are rare. In
15%–30% of cases, SCA is associated with von Hippel–
Lindau (VHL) disease [21].
Imaging findings of SCAs are markedly dependent
on their macroscopic appearance. Typically SCA has
a microcystic appearance and presents as a well-
circumscribed mass with multilobulate sharp margins
and an internal sponge-like architecture due to the
presence of innumerable microcysts (1–5 mm), seldom
with rare larger cysts (>2 cm) peripherally located. A
central stellate scar is typically visible, which can be
calcified due to calcium deposits [22]. These findings
are recognized in about two-thirds of cases [16]. Less
frequently SCAs appear as a macrocystic or oligocystic
mass, characterized by a small number of cysts > 2 cm
which lack a central scar and are often indistinguishable
from other cystic masses of the pancreas, especially
mucinous cystic tumors [22–24]. In microcystic form, at
ultrasound SCAs appear as a mass with no posterior
acoustic enhancement and a ‘honeycomb’ architecture
(Fig. 3(a)). Due to the presence of thin-walled small cysts
and a thick fibrous stroma, SCAs can be homogeneously
hyperechoic at US, thus simulating a solid mass. At
CT on unenhanced images SCA is hypodense (Figs 2(a)
and 3(b)) or isodense to normal parenchyma, with a
bulge in the contour of the gland; calcifications are
well recognized, located in the center of the lesion.
After contrast media administration, internal septa appear
hyperdense due to contrast uptake, with the central
fibrous scar visible (Figs 2(b), (e) and 3(c)–(e)). When
SCA is small it can be difficult to characterize with CT,
as it can appear as a solid mass (Fig. 3(b)–(d)); in this
case, the great sensitivity of MR to static fluids with
highly T2-weighted sequences permits demonstration
of its fluid content (Fig. 3(e)), thus allowing accurate
characterization. In fact, MR is assuming a preeminent
role in the evaluation of cystic tumors of the pancreas,
giving accurate information on the structure of the
lesion (Figs 2(c)–(e) and 3(f)–(i)). Magnetic resonance
cholangiopancreatography (MRCP) depicts the relation-
ship of the lesion with the m.p.d. (Fig. 2(h)), thus
permitting the differentiation between peripheral and
intraductal cystic tumors. However, in some cases the
close relationship between the cystic lesion and the
m.p.d. does not exclude the presence of a communication
(Figs 3(i) and 4); in these cases endoscopic retrograde
cholangiopancreatography (ERCP) is still fundamental in
the differential diagnosis (Fig. 4(b)). Contrast-enhanced
MR gives the same information as CT, with clear
demonstration of the enhancement of both the septa
and the walls (Figs 2(e) and 3(h)). The main limitation
of MR is its insensitivity to calcifications, which are
better recognized with US or CT [25]. When associated
with VHL disease, cystic lesions are multifocal and can
involve the pancreatic gland diffusely (Fig. 5).
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(a) (b) (c)
Figure 5 A 25-year-old woman with von Hippel–Lindau disease. The pancreas appears completely
substituted by multiple small cysts which appear hyperintense on T2w images (HASTE) (a). After injection
of paramagnetic CM the thin septa among the cysts show a discrete enhancement (b). (c) MRCP.
(a) (b) (c)
Figure 6 A 68-year-old man with a serous cystic tumor. At MR a macrocystic unilocular lesion is appreciable
in the tail of the pancreas. The lesion is hyperintense on T2 HASTE (a), and does not show significant
enhancement after injection of paramagnetic CM (b). (c) CT performed 5 years earlier: the lesion is unchanged.
(a) (b) (c)
Figure 7 A 55-year-old woman with a mucinous cystic tumor. (a) At MR a small cyst in the body of the
pancreas can be appreciated (arrowhead). (b) At CT performed 2 years later the cyst shows significant growth.
(c) At MR 1 year later the lesion is further enlarged with macrocystic unilocular pattern and some small defects
in the wall (arrowhead).
Oligo- or macrocystic forms of SCA, on the other
hand, have a nonspecific appearance which makes
them indistinguishable from other cystic lesions of the
pancreas in all imaging modalities (Figs 6 and 7).
Mucinous cystic neoplasms
Mucinous cystic neoplasms (MCNs) are found almost
exclusively in women. Histologically MCNs are formed
by mucin-producing epithelial cells supported by an
ovarian-type stroma [26]. According to the grade of
epithelial dysplasia, they can be classified into ade-
noma, border-line tumor or carcinoma, invasive or non-
invasive [16]. The peak age is the fifth decade, but a wide
range of ages is affected. With advancing age the grade
of the tumor worsens; this suggests an evolution from
benign to malignant [26], as confirmed by the presence
of the different degrees of differentiation, from benign to
overtly malignant, in the same lesion [27].
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Figure 8 A 66-year-old woman with a mucinous cystic adenocarcinoma. At US (a) a large multilocular cyst
with thick septa is appreciable in the body-tail of the pancreas. After injection of second-generation ultrasound
contrast agent (Sonovue, Bracco, Italy) (b) the wall and septa show significant enhancement, with infiltration
of the splenic artery (arrow). (Courtesy of Mirko D’Onofrio, MD.)
(a) (b)
Figure 9 Mucinous cystic adenocarcinoma, two different cases at CT. After injection of CM the thick wall (a)
and the solid component (∗ in b) show significant enhancement.
(a) (b) (c)
Figure 10 ((a), (b)) Pseudocyst in a 70-year-old woman with a previous history of severe acute pancreatitis.
A large unilocular cyst is appreciable in the tail of the pancreas with a solid component which does not show
significant enhancement after injection of CM (arrowhead in (b)). (c) Coronal MPR.
MCN is located predominantly in the body-tail of the
pancreas; when located in the head of the pancreas,
mucinous cystadenocarcinoma is more prevalent [26]. It
is important to recognize this entity in an early phase of
development, as prognosis of in situ carcinoma is much
better than that of infiltrative carcinoma, which has a
prognosis similar to that of ductal adenocarcinoma [26].
As for SCAs, symptoms for MCNs are nonspecific,
with some degree of abdominal pain or discomfort,
seldom referred to the pancreatic region. For advanced
malignant lesions, clinical signs, such as dyspepsia,
pain, weight loss and jaundice, may be more evi-
dent [28].
Imaging characteristics are again dependent on the
macroscopic appearance. MCNs appear as a round mass
with sharp margins with two main patterns, uni- or
multilocular macrocysts [29]. A macrocystic multilocular
pattern is the most typical [30], while a unicystic
appearance is similar to many other cystic lesions. In
the absence of a history of pancreatitis, the correct
diagnosis of a unicystic lesion with a thin wall is
possible only after resection (Fig. 7) [31–33]. At US
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(a) (b) (c)
Figure 11 A 28-year-old woman with a solid pseudopapillary tumor, cystic variant. At contrast-enhanced US
(a) a small cystic lesion with sharp margins and an enhanced solid component (arrowhead) is appreciable in
the body of the pancreas. With MR the lesion is hyperintense on T2w images (b) (True FISP), while the solid
component shows enhancement after CM injection (arrow in (c)).
(a) (b)
Figure 12 A 47-year-old man with cystic endocrine tumor. AtMR a large lesion with thick walls is appreciable
in the head of the pancreas. The lesion is hyperintense on T2w (a) with significant dilation of the main
pancreatic duct (arrow). After injection of paramagnetic CM a significant enhancement of the wall of the
lesion can be appreciated (b).
multicystic MCN appears as a deeply hypoechoic mass
with sharp margins; the wall has various thickness [30],
with mural vegetation or parietal calcifications [32]. Thick
septa and/or papillary proliferations are suggestive of
the malignant degeneration of MCN (Fig. 8(a)) [32].
With contrast-enhanced US (CEUS), the wall and septa
show variable degrees of enhancement (Fig. 8(b)). At
unenhanced CT calcifications are clearly recognizable.
The density of MCNs can vary from hypodense to
hyperdense due to hemorrhage or mucin content [34].
After CM injection either the wall (Fig. 9(a)) and the
septa or solid component (Fig. 9(b)) show variable
enhancement, although less than normal parenchyma [35].
However, pseudocysts with necrotic debris, which can
simulate parietal nodules, do not show significant
enhancement after CM injection (Fig. 10(a)–(c)). The
imaging triad of calcifications, thick walls, and mural
vegetation is predictive of malignant degeneration in 95%
of cases [24]. MR with heavily T2-weighted sequences
allows better identification of the thin septa than CT but
has less sensitivity in identifying the calcifications. With
MRCP the lack of communication between the MCN and
the m.p.d. can be easily demonstrated, thus excluding an
intraductal origin of neoplasia [36–38].
As a differential diagnosis for the macrocystic pattern
of SCA (Figs 6 and 7), the cystic variant of solid
pseudopapillary tumor (Fig. 11), the cystic endocrine
tumor (Fig. 12) should be considered [30]. Clinical history
(MEN syndrome) or the evidence of hemorrhage inside
the lesion (pseudopapillary tumor) can help in the
diagnosis.
Intraductal papillary mucinous tumor
Intraductal papillary mucinous tumor (IPMT) was first
described in 1982 [39]. In the last 10 years it has been
increasingly described [40–42], thanks to the evolution
of imaging modalities, especially MR, and to more
widespread knowledge of this entity. In the past, many
IPMTs were misdiagnosed as chronic pancreatitis. It has
been classically described as a mucin-secreting tumor
with dilation of the m.p.d. and a protruding papilla [39].
IPMT can affect the m.p.d. and/or a branch-side duct.
The tumor originates from the ductal epithelium and can
evolve from slight dysplasia to infiltrating carcinoma over
time with different aspects seen in the same lesion [43–45].
From the imaging point of view it is important not only
to correctly differentiate IPMT from chronic pancreatitis,
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(a)
(d) (e)
(c)(b)
Figure 13 An 83-year-old man with a history of abdominal pain and the onset of jaundice. Diffuse IPMT.
On T2w images (a) a diffuse dilation of the main pancreatic duct is appreciable. With coronal MRCP (b) the
dilation of the main pancreatic duct as well as of the biliary system can be depicted as a whole. A bulging of
both major and minor papillae in the duodenal lumen can be appreciated (arrows), but is better depicted on
coronal HASTE (c). At the uncinate process level a small defect in a dilated secondary duct can be seen (d),
which shows significant enhancement after paramagnetic CM injection (arrow in (e)).
(a) (b) (c)
Figure 14 A 75-year-old man with chance detection of pancreatic cyst at US performed as part of a routine
check-up. Branch duct IPMT. With MRCP (a) a large plurilobular cyst in the head of the pancreas can be
appreciated with normal m.p.d. ((b), (c)) Coronal HASTE: the lesion presents thin septa, no solid component,
and a small communication with the m.p.d. can be appreciated (arrow in (c)).
but also to suggest the histological grading of the tumor.
In fact the only valid therapeutic option for IPMT is
partial or total pancreatectomy, which in the case of a
benign IPMT would amount to overtreatment, especially
in branch-duct type [46,47]. Thus, in order to achieve the
correct management of these lesions, it is important to
obtain all the clinical information and to correlate with
imaging findings. IPMT affects patients in theirs 60s to
70s, with an equal distribution between men and women,
while chronic pancreatitis is more frequent during the
40s [48]. When located in the m.p.d. it is clinically
characterized by recurrent abdominal pain simulating
chronic pancreatitis [49,50], secondary to the obstruction
of the pancreatic duct as a result of the hypersecretion of
mucin [51]. In a small percentage (<2%) of cases, IMPT
can provoke an acute severe pancreatitis [51]. In about
50% of cases patients complain of weight loss; in the
early phase this is secondary to the pain evoked by food
consumption while in the advanced phase it is secondary
to the malignant degeneration of IPMT [50]. About 10%
of the patients suffer from diabetes, and the rapid onset of
diabetes is highly suggestive of a malignant degeneration
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of IPMT [40,51]. In a similar way, the onset of jaundice
is suggestive of IPMT in an advanced stage [42]. When
IPMT is limited to side branch ducts it is almost always
asymptomatic and becomes clinically evident when there
is involvement of the m.p.d., with the same symptoms as
an IPMT of the m.p.d.
There is common agreement that the only valid
therapeutic option for IPMT of the m.p.d. as well as
for side branch IPMT with involvement of the m.p.d., is
surgical resection [52], as they are malignant at the time
of the diagnosis in most of the cases. However, branch-
duct type IPMT with a diameter < 3 cm, thin walls, and
with no solid component or involvement of the m.p.d.
can be followed-up [47,53,54], as most are asymptomatic,
benign (hyperplasia-adenoma), and exhibit very slow
growth [52,55].
IPMT of the m.p.d. can present as segmental or
diffuse. When the entire duct is involved, this tumor can
be confused with chronic pancreatitis [56,57]. Segmental
IPMT is very difficult to diagnose as it presents as
a nonspecific segmental dilation of the m.p.d. without
a clear cause of obstruction or a previous pancreatitis
with post-inflammatory stenosis. The affected segment
tends to enlarge with dilatation of the collateral ducts.
When the lesion is localized in the head of the pancreas,
there is a dilatation of the m.p.d. upstream, secondary
to the obstruction of the outflow of pancreatic juice,
thus simulating a diffuse IPMT [58]. ERCP is able to
characterize the lesion, with a clear demonstration of
endoluminal defects and the possibility of aspirating the
pancreatic juice in order to demonstrate the presence
of mucin [59]. Diffuse IPMT presents as a dilatation of
the entire m.p.d. (Fig. 13(a), (b)) often indistinguishable
from obstructive chronic pancreatitis [41,56,57]. In diffuse
IPMT there is frequent cystic dilation of branch ducts,
especially in the uncinate process and in the tail of the
pancreas [60]; moreover, in IPMT a bulging papilla into
the duodenum can be observed, especially with CT or
MR (Fig. 13(c)) after distension of the intestinal lumen
with water or contrast agent [56,61]. This latter observation
is easily obtained with ERCP, which can also observe the
mucin leaking into the papilla [62], making the diagnosis
certain. However, in some cases ERCP is unable to
opacify the m.p.d. owing to the reflux of contrast
agent into the duodenum secondary to the patulous
papilla [63] or to the obstructive dense mucin, which
can also hinder the opacification of branch ducts [62].
MRCP can overcome the limitation of ERCP with a
constant demonstration of branch ducts [64], thus giving
an exact definition of the extent of IPMT. Both mucin
and papillary growth appear hyperechoic at US; the solid
component is better recognized at CT, especially after
CM injection, or with MR, where it appears hypointense
on T2-weighted MR sequences, showing enhancement
after paramagnetic CM injection (Fig. 13(d), (e)) [58,61,65].
IPMT of the branch ducts is easily visualized as
a cystic dilation of branch ducts (Fig. 14) and is
increasingly diagnosed by chance during imaging studies
performed for other reasons than the pancreas [66,67].
They are more often located in the uncinate process,
less frequently in the other portions of the pancreas,
especially the tail [67]. In 30% of cases IPMT is multifocal
(Fig. 15). It appears as a round or oval lesion with
multilobulated margins (Fig. 14). Cystic lesions converge
in a ductal branch which communicates with the m.p.d.;
this communication can be easily demonstrated with
multislice CT by using thin collimation and is even better
demonstrated withMRCP (Fig. 14(c)) [68]. Sometimes the
communication between the IPMT of the branch duct
and the m.p.d. is not easily demonstrated; in such cases
the administration of secretin with MRCP can facilitate
the visualization of the communication, but sometimes
even after secretin the communication cannot be demon-
strated. In these cases ERCP can solve the diagnostic
problem.
Figure 15 A 72-year-old man with recurrent
episodes of acute pancreatitis. Segmental m.p.d and
branch duct IPMT. MRCP. Branch duct dilations
located at the head and tail of the pancreas (arrows).
Mild segmental dilation of m.p.d. at the tail (asterisk).
Solid pseudopapillary tumor
Solid pseudopapillary tumor (SPT) is the least frequent
cystic tumor of the pancreas whose origin is still
uncertain. Since its first description in 1959, it has gone
under different names and it was only in 1996 that
the World Health Organization (WHO) renamed this
tumor as SPT [8]. It has a low malignant potential and
a favorable prognosis. It may affect any age, but most
often affects young women in their 30s [69]. Clinically
it is fairly nonspecific, with abdominal pain as the main
symptom, sometimes together with a palpable mass. The
low malignant potential of the lesion is demonstrated
by its large size at the time of the diagnosis [70]. The
tumor appears as a round, well-encapsulated mass [71].
The content of the lesion is solid with a variable amount
of necrosis or hemorrhage, responsible for its frequent
cystic appearance (Fig. 11). In a series of 56 patients with
SPT, calcifications were found in 29% of the cases [72].
After contrast agent administration the solid component
of the tumor appears well vascularized with all imaging
techniques (Fig. 11(a), (c)). When fresh hemorrhage is
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present, it is well recognized by MR, with high signal
intensity on T1-weighted sequences and fluid–debris
level [72,73]. When large cystic changes are present, SPT
appears as a macrocystic uni- or multilocular lesion,
similarly to MCN; in this situation the young age of the
patient helps in the differential diagnosis.
Conclusion
In conclusion, cystic tumors of the pancreas represent a
diagnostic challenge for both radiologists and clinicians
because of their overlapping clinical, radiological,
and pathologic features. Although less prevalent than
previously thought, pseudocysts are the most frequent
cystic lesions of the pancreas, and a history of pancreatitis
is an important factor in suggesting a diagnosis of
pseudocyst, although it cannot exclude the coexistence
of a pancreatic cystic tumor. The diagnosis of SCA
can be considered certain when based on the finding
of a microcystic or mixed (micro- and macrocystic)
pattern; the diagnosis of either SPT (solid and fluid
structure) or MCN (multilocular macrocystic pattern) is
only presumptive, and all cystic tumors and tumor-like
conditions may present a macrocystic uni- or multilocular
pattern. Finally, even small cystic lesions of the pancreas
appear to have the potential to progress to malignancy [74],
and at least need follow-up with repeat imaging.
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